Our pipeline

Mereo Discover Our Pipeline

At Mereo, we unlock the potential of rare disease therapies that were not being progressed in pharmaceutical or biotechnology companies – creating new possibilities for all our stakeholders, from our investors to the patients that need us most.

We have already delivered five successful Phase 2 studies and a Phase 1b/2 ongoing. Our pipeline currently consists of six clinical-stage product candidates. Click below to see the relevant scientific publications for our products. 

Core programs


Setrusumab (BPS804)

For the potential treatment of Osteogenesis Imperfecta (“OI”), a rare genetic bone condition affecting children and adults.


Alvelestat (MPH966)

For the potential treatment of severe Alpha-1 Antitrypsin Deficiency-Related Lung Disease (AATD-LD) and Bronchiolitis Obliterans Syndrome (BOS).


Etigilimab (MPH313)

For the potential treatment of patients with advanced or metastatic
solid tumors.

Core programs

Partnered and Partnering Opportunities on Non-Core Programs

We have two additional programs with current partnering opportunities. Navicixizumab has been licensed out to OncXerna. 


Navicixizumab (OMP305B83)

For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.


Acumapimod (BCT197)

For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).


Leflutrozole (BGS649)

For the potential treatment of male infertility associated with hypogonadotropic hypogonadism (“HH”).

Partnered and partnering opportunities on non-core programs

Pipeline News

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
24 October 2022

Mereo BioPharma today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD). The update will include commentary from and Q&A with leading pulmonary experts, further to the receipt of Fast Track Designation for alvelestat from the FDA announced on October 17, 2022.

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
17 October 2022

Mereo BioPharma today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational oral neutrophil elastase inhibitor, alvelestat (MPH-966).

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors
12 September 2022

Mereo BioPharma Group today reported updated clinical data and promising biomarker data from ACTIVATE, a Phase 1b/ 2 study of anti-TIGIT antibody, etigilimab, in combination with nivolumab, in select recurrent advanced / metastatic solid tumors. These biomarker data were presented at a poster session at the 2022 European Society of Medical Oncology (ESMO) Annual Meeting on September 10, 2022.

Mereo BioPharma and Ultragenyx to Present Setrusumab Data Update at ASBMR
09 September 2022

Mereo BioPharma and Ultragenyx Pharmaceutical Inc. today announced that additional data relevant to setrusumab will be presented at the American Society for Bone and Mineral Research 2022 Annual Meeting (ASBMR) being held September 9-12, 2022, in Austin, Texas.